ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt
Release Date: 02/24/2014

ClinicalTrials.gov ID: NCT01224015

Study Identification

Unique Protocol ID:	191622-104
Brief Title:	Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
Official Title:	
Secondary IDs:	2010-021271-83 [EudraCT Number]

Study Status

Record Verification:	February 2014
Overall Status:	Completed
Study Start:	May 2011
Primary Completion:	October 2011 [Actual]
Study Completion:	February 2012 [Actual]

Sponsor/Collaborators

Sponsor:	Allergan
Responsible Party:	Sponsor
Collaborators:	

Oversight

FDA Regulated?:	Yes
Applicable Trial?:	Section 801 Clinical Trial? Yes Delayed Posting? No

IND/IDE Protocol?:	Yes
IND/IDE Information:	Grantor: CDER IND/IDE Number: BB-IND 8142 Serial Number: Has Expanded Access? No
Review Board:	Approval Status: Board Name: Board Affiliation: Phone: Email:
Data Monitoring?:	No
Plan to Share Data?:	
Oversight Authorities:	United States: Food and Drug Administration

Study Description

Brief Summary:	This study will evaluate the safety and efficacy of botulinum toxin type A compared to placebo for the treatment of Crow's Feet Lines and Frown Lines (Facial Rhytides) for patients who successfully completed Study 191622-099.
Detailed Description:	

Conditions

Conditions:	Facial Rhytides Crow's Feet Lines Glabellar Lines
Keywords:	

Study Design

Study Type:	Interventional
Primary Purpose:	Treatment
Study Phase:	Phase 3
Intervention Model:	Parallel Assignment
Number of Arms:	3
Masking:	Double Blind (Subject, Investigator)

Allocation:	Randomized
Endpoint Classification:	Safety/Efficacy Study
Enrollment:	684 [Actual]

Arms and Interventions

Arms	Assigned Interventions
onabotulinumtoxinA 24U 24 units (U) onabotulinumtoxinA (botulinum toxin Type A) total dose and placebo injected into bilateral Crow’s Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.	Drug: normal saline Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study. Biological/Vaccine: onabotulinumtoxinA 24 U 24 units onabotulinumtoxinA (botulinum toxin type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study. Other Names: • BOTOX® • BOTOX® Cosmetic • onabotulinumtoxinA
Placebo Comparator: placebo (normal saline) Normal Saline (placebo) injected into bilateral Crow’s Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.	Drug: normal saline Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
Experimental: onabotulinumtoxinA 44U 44 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow’s Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.	Biological/Vaccine: onabotulinumtoxinA 44 U 44 units onabotulinumtoxinA (botulinum toxin type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study. Other Names: • BOTOX® • BOTOX® Cosmetic • onabotulinumtoxinA

Outcome Measures

[See Results Section.]

Eligibility

Minimum Age: 18 Years

Maximum Age:

Gender: Both

Accepts Healthy Volunteers?: No

Criteria: Inclusion Criteria:

- Successfully completed Study 191622-099

Exclusion Criteria:

- Known immunization or hypersensitivity to botulinum toxin of any serotype
- Anticipated need for treatment with botulinum toxin of any serotype during the study (except for study treatment)
- Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral sclerosis
- Anticipated need for surgery or hospitalization during the study

Contacts/Locations

Study Officials: Medical Director
Study Director
Allergan, Inc.

Locations: United States, California
Newport Beach, California, United States

Canada, British Columbia
Vancouver, British Columbia, Canada

France
Antibes, France

Germany
Berlin, Germany

References

Citations:

Links:

Study Data/Documents:

Study Results

Participant Flow

Pre-Assignment Details	Extension study for patients who participated in study 191622-099

Reporting Groups

	Description
onabotulinumtoxinA 44U	44 units (U) onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients received up to 2 treatments during the study.
onabotulinumtoxinA 24U	24 units onabotulinumtoxinA (botulinum toxin Type A) total dose and placebo injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients received up to 2 treatments during the study.
Placebo (Normal Saline)	Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients received up to 2 treatments during the study.

Overall Study

	onabotulinumtoxinA 44U	onabotulinumtoxinA 24U	Placebo (Normal Saline)
Started	361	227	96
Completed	347	211	83
Not Completed	14	16	13

Baseline Characteristics

Reporting Groups

	Description
onabotulinumtoxinA 44U	44 units (U) onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients received up to 2 treatments during the study.
onabotulinumtoxinA 24U	24 units onabotulinumtoxinA (botulinum toxin Type A) total dose and placebo injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients received up to 2 treatments during the study.
Placebo (Normal Saline)	Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients received up to 2 treatments during the study.

Baseline Measures

	onabotulinumtoxinA 44U	onabotulinumtoxinA 24U	Placebo (Normal Saline)	Total
Number of Participants	361	227	96	684
Age, Customized [units: Participants]				
<45 Years	105	68	33	206
45 to 65 Years	241	148	59	448
>65 Years	15	11	4	30
Gender, Male/Female [units: Participants]				
Female	315	203	80	598
Male	46	24	16	86

Outcome Measures

1. Primary Outcome Measure:

Measure Title	Percentage of Participants Achieving a Grade of None or Mild at Maximum Smile Based on the Investigator Facial Wrinkle Scale Assessment of the Severity of Crow's Feet Lines
Measure Description	The investigator assessed the severity of the patient's Crow's Feet Lines at maximum smile using the 4-point Facial Wrinkle Scale: 0=none, 1=mild, 2=moderate or 3=severe. The percentage of participants with a score of none or mild at Day 30 is reported.
Time Frame	Day 30
Safety Issue?	No

Analysis Population Description

Participants from the Intent-to-treat population, consisting of all randomized participants with data available for analysis.

Reporting Groups

	Description
onabotulinumtoxinA 44U	44 units (U) onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients received up to 2 treatments during the study.
onabotulinumtoxinA 24U	24 units onabotulinumtoxinA (botulinum toxin Type A) total dose and placebo injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients received up to 2 treatments during the study.
Placebo (Normal Saline)	Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients received up to 2 treatments during the study.

Measured Values

	onabotulinumtoxinA 44U	onabotulinumtoxinA 24U	Placebo (Normal Saline)
Number of Participants Analyzed	349	223	95
Percentage of Participants Achieving a Grade of None or Mild at Maximum Smile Based on the Investigator Facial Wrinkle Scale Assessment of the Severity of Crow's Feet Lines [units: Percentage of participants]	63.6	56.5	1.1

Reported Adverse Events

Time Frame	[Not specified]
Additional Description	The safety population (all randomized participants who received study drug) was used to calculate the number of participants at risk for Serious Adverse Events and Adverse Events.

Reporting Groups

	Description
onabotulinumtoxinA 44U	44 units (U) onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients received up to 2 treatments during the study.
onabotulinumtoxinA 24U	24 units onabotulinumtoxinA (botulinum toxin Type A) total dose and placebo injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients received up to 2 treatments during the study.
Placebo (Normal Saline)	Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients received up to 2 treatments during the study.

Serious Adverse Events

	onabotulinumtoxinA 44U	onabotulinumtoxinA 24U	Placebo (Normal Saline)
	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)
Total	6/349 (1.72%)	1/223 (0.45%)	1/95 (1.05%)
Gastrointestinal disorders			
Diarrhoea [A] *	0/349 (0%)	0/223 (0%)	1/95 (1.05%)
Intestinal obstruction [A] †	1/349 (0.29%)	0/223 (0%)	0/95 (0%)

	onabotulinumtoxinA 44U	onabotulinumtoxinA 24U	Placebo (Normal Saline)
	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)
Infections and infestations			
Gastrointestinal infection [A] †	1/349 (0.29%)	0/223 (0%)	0/95 (0%)
Infected bites [A] †	1/349 (0.29%)	0/223 (0%)	0/95 (0%)
Metabolism and nutrition disorders			
Dehydration [A] †	0/349 (0%)	0/223 (0%)	1/95 (1.05%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma [A] †	1/349 (0.29%)	0/223 (0%)	0/95 (0%)
Bowen's disease [A] †	1/349 (0.29%)	0/223 (0%)	0/95 (0%)
Breast cancer [A] †	0/349 (0%)	1/223 (0.45%)	0/95 (0%)
Malignant melanoma in situ [A] †	1/349 (0.29%)	0/223 (0%)	0/95 (0%)

† Indicates events were collected by systematic assessment.
* Indicates events were collected by non-systematic methods.
A Term from vocabulary, MedDRA 14.1

Other Adverse Events

Frequency Threshold Above Which Other Adverse Events are Reported: 5%

	onabotulinumtoxinA 44U	onabotulinumtoxinA 24U	Placebo (Normal Saline)
	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)
Total	44/349 (12.61%)	23/223 (10.31%)	15/95 (15.79%)
General disorders			
Injection site haematoma [A] *	20/349 (5.73%)	11/223 (4.93%)	6/95 (6.32%)
Infections and infestations			
Nasopharyngitis [A] *	6/349 (1.72%)	9/223 (4.04%)	6/95 (6.32%)
Nervous system disorders			
Headache [A] *	18/349 (5.16%)	3/223 (1.35%)	3/95 (3.16%)

* Indicates events were collected by non-systematic methods.
A Term from vocabulary, MedDRA 14.1

Limitations and Caveats

[Not specified]

More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.

Results Point of Contact:

Name/Official Title: Therapeutic Area Head,
Organization: Allergan, Inc
Phone: 714-246-4500
Email: clinicaltrials@allergan.com